The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Inception Date: 20/12/2011
Primary Benchmark: MVIS US Listed Biotech 25 NR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.4%
Management Expense Ratio: 0.35 %
|AMGN||Amgen Inc.||12.83 %|
|GILD||Gilead Sciences Inc.||11.70 %|
|CELG||Celgene Corporation||8.02 %|
|BIIB||Biogen Inc.||6.25 %|
|VRTX||Vertex Pharmaceuticals Incorporated||5.56 %|
|AGN||Allergan plc||5.42 %|
|SHPG||Shire plc||5.00 %|
|ALXN||Alexion Pharmaceuticals Inc.||4.85 %|
|ILMN||Illumina Inc.||4.82 %|
|IQV||IQVIA Holdings Inc.||4.42 %|
|IBB||iShares Nasdaq Biotechnology I..||0.47 %||
|PSCH||PowerShares S&P SmallCap Healt..||0.29 %||
|PPH||VanEck Vectors Pharmaceutical ..||0.35 %||
|PTH||PowerShares DWA Healthcare Mom..||0.60 %||
|CNCR||Loncar Cancer Immunotherapy ET..||0.79 %||
|BTEC||Principal Healthcare Innovator..||0.42 %||
|GNRX||VanEck Vectors Generic Drugs E..||0.55 %||
|FTXH||First Trust Nasdaq Pharmaceuti..||0.60 %||
|SLIM||The Obesity ETF||0.50 %||
|LNGR||Global X Longevity Thematic ET..||0.52 %||
|Market Performance vs.
|Market Performance vs. Exchange (NASDAQ Global Market)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||20.92%||27%||F||63%||D|
|Risk Adjusted Return||67.17%||64%||D||67%||D+|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.